About
Shire plc was a UK-founded Jersey-registered specialty biopharmaceutical company. Originating in the United Kingdom with an operational base in the United States, its brands and products included Vyvanse, Lialda, and Adderall XR. Shire was acquired by Takeda Pharmaceutical Company on 8 January 2019.
Shire was a global biotechnology company focused on serving people with rare diseases and other highly specialized conditions. The company's products were available in 100+ countries across core therapeutic areas including Hematology, Immunology, Neuroscience, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; a growing franchise in Oncology; and an emerging pipeline in Ophthalmics.
The original corporate headquarters was located in Basingstoke, Hampshire, England. Main offices were located in Dublin, Ireland, the United States in Cambridge, Massachusetts, and Chicago, Illinois, and in Zug, Switzerland. In addition, Shire owned manufacturing sites in Lexington, Massachusetts, and Social Circle, Georgia. Shire's headquarters in Lexington, Massachusetts, were integrated with Takeda's new U.S. headquarters, which were relocated from Deerfield, Illinois, to the Boston area.
From Wikipedia’s article on Rolf Stahel, shared under CC BY-SA 4.0.2
Companies
Early life and education
- Date not recordedHarvard Business School3
Career
Occupation: business executive.5
Flemming Ørnskov, was the company's chief executive officer through 8 January 2019 with Takeda's acquisition of Shire. Ginger Gregory as chief human resources officer, Jeffrey Poulton as CFO, and Philip Vickers as head of R&D. James Bowling vacated his position as interim CFO in the aftermath of the collapse of the AbbVie inversion deal. The chair of Shire's board of directors was Susan Kilsby.
From Wikipedia’s article on Rolf Stahel (this version), CC BY-SA 4.0.
Personal life
- CitizenshipSwitzerland6
Legal issues and controversies
False Claims Act violations
In September 2014, Shire reached a $56.5 million settlement with the U.S. Department of Justice for alleged violations of the False Claims Act. The Justice Department alleged that Shire had improperly marketed and promoted Adderall XR, Daytrana, Vyvanse, Pentasa, and Lialda during various periods between 2004 and 2010. The allegations included claims that Shire had made exaggerated and false statements regarding product safety, promoted medications for non-FDA approved off-label use, and marketed products on unsubstantiated claims of beneficial side effects, including reductions in criminality, traffic accidents, sexually transmitted infections, and divorce rates.
Illegal promotion of Dermagraft
In August 2017, Shire reached a $350 million settlement with the Department of Justice for violations of the same act, regarding the unlawful promotion of Shire's product Dermagraft.
From Wikipedia’s article on Rolf Stahel (this version), CC BY-SA 4.0.
Awards
- Date not recordedFellow of the Royal Society of Arts7
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1WikidataRolf Stahel on Wikidata
- 2WikipediaRolf Stahel on Wikipedia
- 3
- 4
- 5
- 6
- 7WikidataRolf Stahel: award, on Wikidata
- 8